<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00638872</url>
  </required_header>
  <id_info>
    <org_study_id>PLA/01/06</org_study_id>
    <nct_id>NCT00638872</nct_id>
  </id_info>
  <brief_title>Polydeoxyribonucleotide -Placentex Mastelli(Pdrn) for the Treatment of Diabetic Ulcers</brief_title>
  <official_title>Diabetic Foot Ulcers and Use of PDRN (Polydeoxyribonucleotide -Placentex Mastelli) as a Treatment for Wound Healing.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Messina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Messina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to evaluate the efficacy of the polydeoxyribonucleotide in&#xD;
      improving the healing of diabetic foot ulcers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will involve diabetic patients with foot ulcers who meet the inclusion/exclusion&#xD;
      criteria. At least 200 patients aged 45-80yrs will be enrolled in the study and randomly&#xD;
      allocated to receive the active drug or the placebo in indistinguishable formulations. After&#xD;
      2 months closure rate of the ulcer will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction of ulcer rate</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability of the compound</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>Diabetic Ulcer</condition>
  <condition>Foot Ulcer Unhealed</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDRN</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polydeoxyribonucleotide</intervention_name>
    <description>3 times a week perilesional or intramuscular injections</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>0.9% NaCl</intervention_name>
    <description>same as PDRN</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged 45-80yrs&#xD;
&#xD;
          -  Minimum schooling 5yrs&#xD;
&#xD;
          -  Type I or II diabetes since at least 5yrs with a stable metabolic control&#xD;
&#xD;
          -  Foot ulcer since minimum 2 weeks&#xD;
&#xD;
          -  Ulcer &gt;1cm and &lt;16cm at day 0&#xD;
&#xD;
          -  Ulcer grade 1 or 2 wagner scale&#xD;
&#xD;
          -  Wound free of necrotic debris&#xD;
&#xD;
          -  TcPO2 &gt;29mmHg&#xD;
&#xD;
          -  Not pregnant or lactant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-consenting patient&#xD;
&#xD;
          -  History of alcohol or drug abuse&#xD;
&#xD;
          -  Gangrene on any part of the affected foot&#xD;
&#xD;
          -  Ongoing untreated infections&#xD;
&#xD;
          -  Ulcer over a charcot deformity&#xD;
&#xD;
          -  Use of a systemic cicatrizant drug in the past 10 days&#xD;
&#xD;
          -  Malnutrition&#xD;
&#xD;
          -  Neurological or psychiatric pathologies&#xD;
&#xD;
          -  Liver or kidney insufficiency&#xD;
&#xD;
          -  Corticosteroid or immunosuppressive or cytotoxic therapy&#xD;
&#xD;
          -  Other severe pathologies&#xD;
&#xD;
          -  Proven hypersensitivity to the drug or to any related component&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giulia Cattarini</last_name>
    <role>Study Director</role>
    <affiliation>Mastelli srl, via Bussana Vecchia, Sanremo, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Messina</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>March 12, 2008</study_first_submitted>
  <study_first_submitted_qc>March 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2008</study_first_posted>
  <last_update_submitted>September 10, 2012</last_update_submitted>
  <last_update_submitted_qc>September 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Messina</investigator_affiliation>
    <investigator_full_name>Francesco Squadrito</investigator_full_name>
    <investigator_title>Full Professor of Pharmacology</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>foot ulcer</keyword>
  <keyword>polydeoxyribonucleotide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

